After 48 months , radius bone mineral density was unchanged in the teriparatide to denosumab group ( 00 % [ 95 % CI -13 to 14 ] ) , whereas it decreased by -18 % ( -50 to 13 ) in the denosumab to teriparatide group , and increased by 28 % ( 12-44 ) in the combination to denosumab group ( p = 00075 for the teriparatide to denosumab group vs the combination to denosumab group ; p = 00099 for the denosumab to teriparatide group vs the combination to denosumab group ) .